🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2024-517397-25-00
Completed Phase I

FT819 in B-cell Mediated Autoimmune Diseases

2024-517397-25-00 · tracked via the Priya Life Science EU tracker
Sponsor
Fate Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
30/09/2025
Enrollment target
50
Sites
France, Sweden, Germany

Condition studied

B-cell Mediated Autoimmune Diseases

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-517397-25-00 on CTIS ↗ ← All trials in the EU